8 assets in Hereditary Leiomyomatosis And Renal Cell Cancer

Therapeutic assets addressing Hereditary Leiomyomatosis And Renal Cell Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Atezolizumab Hereditary Leiomyomatosis And Renal Cell Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Dentalfluoro Hereditary Leiomyomatosis And Renal Cell Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Pamiparib Hereditary Leiomyomatosis And Renal Cell Cancer	Jonsson Comprehensive Cancer Center	P2	CCC (53)
13C-Fructose Hereditary Leiomyomatosis And Renal Cell Cancer	University of Texas Southwestern Medical Center	N/A	D (30)
Acetic-1-13C Acid Hereditary Leiomyomatosis And Renal Cell Cancer	University of Texas Southwestern Medical Center	N/A	D (30)
Glucose, Anhydrous Hereditary Leiomyomatosis And Renal Cell Cancer	University of Texas Southwestern Medical Center	N/A	D (30)
Glutamine Hereditary Leiomyomatosis And Renal Cell Cancer	University of Texas Southwestern Medical Center	N/A	D (30)
Lactate Hereditary Leiomyomatosis And Renal Cell Cancer	University of Texas Southwestern Medical Center	N/A	D (30)